ImmuCell
Logotype for ImmuCell Corporation

ImmuCell (ICCC) investor relations material

ImmuCell Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ImmuCell Corporation
Q3 2026 earnings summary13 Nov, 2026

Executive summary

  • Q3 product sales rose 46.0% YoY to $8.040M; net income was $953K versus a $140K loss, driven by First Defense® volume, portfolio expansion and pricing.

  • 9M sales grew 27.8% to $25.584M; net income increased to $4.729M from $1.809M, including a non-recurring $2.0M settlement.

  • Distributor out-the-door volume rose 18% YoY; broader commercial activity and manufacturing execution supported growth.

Financial highlights

  • Q3 product sales were $8.040M versus $5.506M; 9M sales were $25.584M versus $20.018M.

  • Q3 operating income was $958K versus $20K; 9M operating income was $4.862M versus $1.707M, including $2.0M of other operating income.

  • Q3 net income was $953K versus a $140K loss; 9M net income was $4.729M versus $1.809M, including the $2.0M settlement.

  • Adjusted EBITDA was $1.884M in Q3 versus $750K; 9M adjusted EBITDA was $7.289M versus $4.420M.

  • Sept. 30 cash was $7.91M and net working capital was $16.90M, versus $3.81M and $12.97M at Dec. 31, 2025.

Outlook and guidance

  • First Defense® capacity expansion remains targeted for completion in H1 2027 for freeze-drying and year-end 2027 for liquids processing, within the original $8M budget.

  • The expansion requires $6.3M of additional spending as of Sept. 30, 2026; management expects the project to finish on time and within budget.

  • Yield improvements are expected to support demand until added drying capacity comes online; the new freeze dryer is expected to roughly triple freeze-drying capacity.

  • Strong calf values are expected to continue through 2027 and 2028; Functional Feed met full-year targets early.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next ImmuCell earnings date

Logotype for ImmuCell Corporation
Q4 20265 Mar, 2027
ImmuCell
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next ImmuCell earnings date

Logotype for ImmuCell Corporation
Q4 20265 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

ImmuCell Corporation, an animal health company, designs, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle worldwide. It focuses on developing products that improve the health of calves during the period from birth through weaning.